JATS 2016

Headquarters Office
Department of General Thoracic Surgery and Breast and Endocrinological Surgery (SurgeryII), Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
2-5-1 Shikata-cho Kita-ku, Okayama 700-8558, Japan
Congress Management Office
Japan Convention Services, Inc. Kansai Branch
Keihanshin Yodoyabashi Building 2F, 4-4-7 Imabashi, Chuo-ku, Osaka 541-0042, Japan
Tel: +81-6-6221-5933
Fax: +81-6-6221-5938
E-mail: 69jats@convention.co.jp
  • Home
  • Call for Abstracts

Call for Abstracts

Registration must be performed on-line from this website. Click on the Register button at the bottom of the screen to begin the registration process.

1. The presenter and any co-speakers must be Association members.

If you do not belong to the Japanese Association for Thoracic Surgery, please contact with your name and affiliation to the following address; jats-adm@umin.ac.jp

The Japanese Association for Thoracic Surgery
1F Teral Koraku Building, 2-3-27 Koraku, Bunkyo-ku, Tokyo 112-0004, JAPAN
Phone: +81-3-3812-4253 Fax: +81-3-3816-4560
URL: http://www.jpats.org/ E-mail: jats-adm@umin.ac.jp

2. Presentations must be original material that is being presented for the first time.

3. Privacy

The privacy policy of the Japanese Association for Thoracic Surgery in relation to case reports and other medical papers and research presentations is available on the Association's website at the following address: http://square.umin.ac.jp/jats/ja/public/topic/20060207.htm
Please ensure that your presentation complies with the privacy policy.
Any violations of the privacy policy will be treated as the responsibility of the applicant.

4. Copyright over all presentations approved for use at the Congress reverts to the Japanese Association for Thoracic Surgery.

5. Application procedure

1- Application period
Close at noon on Tuesday 12nd April, 2016
Abstract submission has been extended, April 25 (Mon.), 2016 (JST).
2- Submissions
I. Registration method, registration and password
The registration number is automatically generated, but you may choose your own password. The registration number and password can be used to log in and change your details at any time until the final deadline (noon, Tuesday 12nd April, 2016). It is your responsibility to protect your password and other details. It is most important that the registration number and password are kept confidential, since these are required for registration, cancellation, changing and/or amending details and confirmation of receipt and acceptance of the presentation. The Association cannot respond to inquiries regarding security issues.
II. The UMIN Online Presentation
Registration System is compatible with Internet Explorer, Netscape and Safari only. Do not attempt the registration process using any other browser. Safari should be Ver. 2.0.3 (417.9.2) or later.
3- Total length of presentation
The publication language must be in English. The total length of the presentation, including the title, the author's name and the institution, and the name of the co-speaker and the institution, plus the next extract, must be no more than 2,600 characters. Where figures and tables are used, the maximum length of the text extract is 2,199 characters. Figures and tables must be submitted as a single GIF or JPEG file no larger than 300KB (portrait or landscape accepted; size will be reduced to approximately 6*4 cm).
4- Notification of receipt of application
Conventional mail will not be used to notify applicants of receipt of the application and approval of the presentation for inclusion in the Congress. Instead, you will be notified automatically via email (using the email address supplied at the time of registration) once the registration process is complete. If you do not receive a notification email, you can use your registration number and password to check the progress of your application on the Change of Details screen.
5- Approval of presentation
I. Approval of presentations for inclusion in the Congress is determined by the Chairperson based on the recommendations of the Program Committee.
II. Notification of decision: Notification of the Chairperson's decision will be sent via email in early July 2016. The results will also be listed on the website. It is your responsibility to ascertain the status of your application.
III. A shortlist of presentations from the areas of cardiac/vascular, pulmonary.
mediastinal or esophageal surgery will be selected prior to the Congress. The selected presenters will be asked to submit their slides and notes to the Secretariat; these will be used to select Plenary Session presentations.
6- Symposium, Panel Discussion, Worshop, and oral presentation are normally conducted with the use of computers.
*Special Programs
Accidents during Thoracoscopic Surgery, and Intervention for Thoracic Diseases and Treatments
The Most Up-to-Date Perioperative Management for Thoracic Surgery
Treatments for Aorto-Esophageal, Aorto- Bronchial, and Esophago-Bronchial Fistulae
1) (Adult Heart & Lung)
The strategy for the increase in cadaveric donor organs and the organ allocation system for recipients
【outline】While postoperative outcomes of heart and lung transplantation in Japan are better than those of the registry report from the International Association of Heart and Lung Transplantation, the shortage of organ donation is critical and the mortality rate of candidates on waiting list is quite high compared with other countries. In these conditions, the increasing number of the donor organs and setting an appropriate system of organ allocation are important issues. The strategy for decreasing the mortality rate of the candidates will be discussed.
2) (Adult Heart (Ischemic))
Long-Term Surgical Results of CABG for Patients with Low Cardiac Function
【outline】The superiority of CABG for patients with triple vessel disease over PCI has been shown in many clinical studies; this superiority is prominent especially in patients with diabetes or low cardiac function. However, there are few clinical studies on long-term results of CABG for patients with low cardiac function in Japan. The purpose of this symposium is to evaluate long-term results of isolated CABG in patients with LVEF≤40%, to compare the surgical results in different levels of risk stratification, and to compare surgical results to those of PCI.
3) (Adult Heart (Valve))
Outcomes of reoperative cardiovascular surgery
【outline】The number of reoperation is increasing with advancement of patient's age. In this session surgical technique and transcatheter therapy will be discussed.
4) (Adult Heart (Great Vessel))
Welcome to a new era of aortic arch repair based on past, present, and future deeds
【outline】Various surgical techniques have been devised for the treatment of aortic arch conditions in this past half century. In Japan, such surgical interventions have produced excellent outcomes. In recent years, minimally invasive approaches have been introduced into the field of aortic arch repair in the form of stent grafting, and techniques are becoming even more diversified. In this symposium, therefore, we will shed light on how the treatment of this condition has changed throughout the years, and invite participants to discuss the future of this field.
5) (Congenital)
The 5 years survival of Norwood procedure for Hypoplastic Left Heart syndrome - How to improve the surgical outcome-
【outline】Hypoplastic Left Heart syndrome was one of the most lethal anomalies. However, in this 20 years several surgical modification including RV-PA shunt, DUNK technique, arch plasty, attributed a remarkable improvement of surgical outcome. In this session, the discussion made for surgical modification retrospectively and further improvement of outcome for the Norwood procedure.
6) (Lung 1)
Treatment strategy for malignant pleural mesothelioma (MPM)
【outline】Although the number of patients with MPM is predicted to increase in Japan, the appropriate treatment strategies have not been established. By getting the picture of current status in diagnoses and treatments, the perspectives dealing with MPM will be discussed. Special guests from foreign countries, who are experts of MPM, will join this discussion.
7) (Lung 2)
Chest surgery performed in association with other types of surgery
【outline】Induction therapy is often applied to advanced non-small cell lung cancers or mediastinal tumors invading surrounding organs. To achieve complete resection of these advanced diseases, the sole chest surgical approach is not enough and techniques of cardiovascular, orthopedic, or plastic surgery are occasionally required. Since these cases employed with the extended surgical techniques are rare, we should share these important experiences and transfer those surgical techniques to young doctors.
8) (Esophagus)
Optimization of surgical therapy in multidisciplinary treatment for esophageal cancer
【outline】Although surgery can have the central role of the treatment for esophageal cancer, by the surgery alone, the therapeutic effect may not be enough for the far advanced cases. Recently, the multimodality therapy for the far advanced cancer cases has been introduced, and many facilities have performed the therapy combining with surgery, chemotherapy and radiation. However, the combination way has not been standardized yet, and the methods are still dependent on each facility in fact. In this symposium, we hope to discuss the optimal timing of surgical therapy in multidisciplinary treatment and the best surgical techniques for the far advanced esophageal cancer cases.
panel discussion
1) (Adult Heart (Ischemic))
Ischemic Mitral Regurgitation: How Do You Select Surgical Procedures; Mitral Valve Repair With Subvalvular Procedures, Ring Annuloplasty Only or Mitral Valve Replacement?
【outline】Many clinical studies have shown that there is no advantage of restrictive mitral annuloplasty over mitral valve replacement as a surgical treatment of ischemic mitral regurgitation. However, there is few evidences regarding mitral valve repair with subvalvular procedures. We would like to discuss how we should select surgical procedures; mitral valve repair with subvalvular procedures, ring annuloplasty only or mitral valve replacement.
2) (Adult Heart (Valve))
Late outcomes of surgical treatment for tricuspid regurgitation
【outline】Severe tricuspid regurgitation has an important impact on clinical outcomes and survival in patients with left - sided valve disease. In this session surgical indication and methods will be discussed.
3) (Adult Heart (Great Vessel))
Treatment strategy for chronic type B aortic dissection
【outline】With the recent introduction of TEVAR, new treatment strategies are being considered for the treatment of type B aortic dissection. However, the utility of TEVAR in chronic dissection has not been elucidated as clearly as its utility in the acute phase. In this session, therefore, participants will consider the utility of each mode of treatment for type B aortic dissection, from all aspects without regard to whether the approach is medical management or surgical intervention, not only for early outcomes but also including long-term outcomes.
4) (Lung 1)
Significance of lymphadenectomy in surgical therapy for non-small cell lung cancer (NSCLC): selective dissection versus standard dissection
【outline】The ACOSOGZ0030 randomized control trial performed in North America demonstrated that the standard lymphadenectomy is not needed if there is no metastasis in systematically sampled lymph nodes of c-T2N1M0 or less NSCLCs. After Dr. GE Darling's lecture about this study, we will discuss the indication of both lymphadenectomies and the intraoperative navigation methods.
5) (Lung 2)
Treatment strategy for c-N1 non-small cell lung cancer (NSCLC)
【outline】Initial surgery is often applied to patients with c-T1-2N1M0 NSCLC. However, there are no obvious criteria for image diagnosis of c-N1. Furthermore, we may speculate that a positive #10 lymph node may have a different effect on prognosis between upper-lobe and lower-lobe tumor origins. Focusing on c-N1 NSCLC, the diagnostic criteria, staging or treatment approach will be discussed.
6) (Esophagus)
Standardization of thoracoscopic esophageal cancer surgery and challenging for next stage
【outline】The history of the thoracoscopic esophageal cancer surgery has passed 20 years in Japan. Now, more than 30 percent of esophageal cancer surgery has been performed under thoracoscopy. Originally, thoracoscopic esophagectomy has been done in the left lateral position. However, the surgeons who perform it in the prone position have increased recently. In addition to patient's posture, there are great differences among the facilities about artificial pneumothorax combination, ports position, the timing of the esophageal transection, device selection etc. in the present situation. For these reasons, there are also great disparities among the facilities in surgical outcomes such as the incidence rate of recurrent laryngeal nerve palsy and pneumonia etc. In this panel discussion, we hope to discuss what is the optimal standardization, and what to challenge to next for the safety and less complications in thoracoscopic esophageal surgery.
1) (Adult Heart (Ischemic))
Surgical Strategy for Patients with End-Stage Heart Failure: LVAD and Heart Transplantation Revisited
【outline】Heart Transplantation is the Gold Standard of the treatment for patients with end-stage heart failure. However, under circumstances of lack of donor hearts, alternative treatments should be required, especially in Japan. How is the surgical results of LVAD as an alternative treatment to heart transplantation in the current era? What is the future prospect of LVAD as a destination therapy?
2) (Adult Heart (Valve))
Strategy for aortic stenosis with coronary artery disease in high risk patients.
【outline】CAD is associated in 40-50% of patients with aortic stenosis. Off-pump CABG has become standard operation and transcatheter aortic valve implantation has been introduced in Japan. We have to consider the surgical strategy for aortic stenosis with coronary artery disease in high risk patients.
3) (Adult Heart (Great Vessel))
Challenge and innovation of thoracic aortic surgery
【outline】Surgical techniques for thoracic aortic conditions in Japan are in a process of continuous evolution, and while the radical nature of such approaches are necessary, there is nevertheless also a need to emphasize minimal invasiveness for patients who are elderly and have numerous preoperative complications. In this workshop, presenters will introduce new techniques for treating thoracic aortic conditions (regardless of disease group) that have been developed and devised in recent years. These techniques will be discussed in anticipation of constructing new treatment strategies.
4) (Congenital)
The surgical strategy of PA/VSD combined with MAPCAs -The mid term results and the evaluation of post operative status-
【outline】There are several strategies including staged or one-staged approach in these anomalies. The final goals of this strategy are adequate pulmonary perfusion in each segment of the lung with low pulmonary artery pressure. To achieve these goals, we deeply discuss with the appropriate strategy and post-operative hemodynamic evaluation.
5) (Lung 1)
Treatment strategy for secondary pneumothorax
【outline】There are a variety of causes of secondary pneumothorax. Therefore, the treatment strategy may be different depending on each cause of the disease. The optimal treatment approach will be discussed based on the background lung diseases.
6) (Lung 2)
Treatment strategy for empyema with fistula
【outline】Management of empyema in association with broncho-pleural fistula after lung resection or intractable pneumothorax is a challenge for thoracic surgeons. According to the annual report 2013 of the Japanese Association for Thoracic Surgery, the surgical mortality rate is extremely high, 6.9% in acute empyema and 4.5% in chronic empyema. We should find out the proper treatment strategy to reduce the mortality.
Oral or Poster Presentation
H. Heart
H-1 congenital heart diseases
H-2 valve diseases
H-3 valvoplasty
H-4 endocarditis
H-5 coronary artery
H-6 complications after myocardial infarction
H-7 aorta
H-8 pacemaker
H-9 arrythmia
H-10 cardiac neoplasms
H-11 cardiomyopathy
H-12 cardiac or cardiopulmonary transplantation
H-13 myocardial protection and metabolism
H-14 extracorporeal circulation
H-15 ventricular assisted system, artificial heart
H-16 cardiac function
H-17 perioperative management, complications
H-18 examination and diagnosis
H-19 molecular biology
H-20 new surgical techniques
H-21 less-invasive surgery
H-22 regenerative medicine
H-23 others
L. Lung
L-1 lung cancer
L-2 metastatic lung cancers
L-3 mediastinal tumors
L-4 Thymus
L-5 pleura and chest wall
L-6 tracheo-bronchus
L-7 emphysematous and bullous lung diseases
L-8 nflammatory lung diseases
L-9 benign lung tumors
L-10 pediatric lung diseases
L-11 video assisted thoracoscopic surgery (VATS)
L-12 lung transplantation
L-13 novel surgical techniques
L-14 perioperative management and complications
L-15 examinations and diagnosis
L-16 artificial materials and organs
L-17 and molecular biology
L-18 medicine
L-19 others
E. Esophagus
E-1 esophageal malignancies
E-2 esophageal benign tumors
E-3 Barrett esophagus
E-4 esophagectomy and lymphadenectomy
E-5 reconstruction and the function of reconstructive organs
E-6 thoracoscopic and laparoscopic Surgery
E-7 endoscopic treatment
E-8 adjuvant therapy
E-9 palliative treatment
E-10 perioperative management and complications
E-11 examination and diagnosis
E-12 multiple cancers
E-13 recurrence and prognosis
E-14 gene and molecular biology
E-15 experimentation and pathology
E-16 others
T. Teaching
T-1 education
T-2 medical economy
T-3 medical policy
T-4 others
7- Presentation format
Information about presentation format and methodology requirements will be released in due course. These requirements are subject to change. Applicants are advised to check the website for the latest information.
8- Video presentations
* Video material must be provided on DVD.
We welcome video presentations on a broad range of themes, including innovative surgical techniques, cases of clinical interest, measures against pitfalls, and inventive auxiliary means. Participants in the clinical video is expected to deliver presentations using a six-minute video (in DVD format). Please submit an abstract in accordance with the above instructions.

Submission Page


Submission  Check and Modfy


Submission  Check and Modfy


For more information about presentations and the registration process, contact the Congress Management Office by fax or email at the following address:
Japan Convention Services, Inc. Kansai Branch
Keihanshin Yodoyabashi Building 2F, 4-4-7 Imabashi, Chuo-ku, Osaka 541-0042, Japan
Tel: +81-6-6221-5933
Fax: +81-6-6221-5938
E-mail: 69jats@convention.co.jp